1887

Abstract

Ribavirin is effective in combination therapies against chronic hepatitis C virus (HCV) infection, although its direct antiviral properties are unclear. We therefore studied the immune-modulatory effects of ribavirin on hepatitis B virus (HBV)- and HCV-specific immune responses. During a 24 week placebo-controlled ribavirin trial in ten patients with chronic HCV infection, HCV antibodies and alanine aminotransferase (ALT) levels decreased transiently whereas the serum levels of HCV RNA remained stable. Effects of ribavirin on human and murine phytohaemagglutinin (PHA)-activated T cells included inhibition of proliferation and modulation of IL-2, IL-4, IFN- and TNF-α levels. HBcAg- and HBeAg-specific IL-2 and IFN- levels were ≥ 25-fold higher in mice immunized with HBV core- or e-antigens (HBcAg, HBeAg) while receiving riba virin compared to untreated mice, but IL-4 and IL-6 remained constant. Concordantly, a slight shift was observed in the IgG subclass distribution of the humoral responses of ribavirin-treated mice to HBeAg and HCV NS3 protein. Ribavirin treatment of HBeAg-transgenic (HBeAg-Tg) mice induced a dose- dependent down-regulation of T helper (Th)2- mediated antibody production to HBeAg. In ribavirin-treated HBeAg-Tg mice anti-HBe IgG1 (positively regulated by Th2 cytokines) decreased simultaneously as both anti-HBe IgG2a (positively regulated byTh1 cytokines) levels and T-cell IFN- production increased, indicating a change in the Th1/Th2 balance. Thus, the present data suggest that ribavirin is not strictly an antiviral compound, but rather it alters the T-cell balance in the immune system.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-79-10-2381
1998-10-01
2022-05-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/79/10/9780043.html?itemId=/content/journal/jgv/10.1099/0022-1317-79-10-2381&mimeType=html&fmt=ahah

References

  1. Agbaria R., Mullen C. A., Hartman N. R., Cooney D. A., Hao Z., Blaese R. M., Johns D. G. 1994; Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction. Molecular Pharmacology 45:777–782
    [Google Scholar]
  2. American Academy of Pediatrics Committee on Infectious Diseases 1996; Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 97137–140
    [Google Scholar]
  3. Balzarini J., Lee C. K., Herdewijn P., De Clercq E. 1991; Mechanism of the potentiating effect of ribavirin on the activity of 2ʹ,3ʹ- dideoxyinosine against human immunodeficiency virus. Journal of Biological Chemistry 266:21509–21514
    [Google Scholar]
  4. Connor E., Morrison S., Lane J., Oleske J., Sonke R. L., Connor J. 1993; Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 37:532–539
    [Google Scholar]
  5. Connors M., Giese N. A., Kulkarni A. B., Firestone C. Y., Morse H. C. R., Murphy B. R. 1994; Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin- inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. Journal of Virology 68:5321–5325
    [Google Scholar]
  6. Di Bisceglie A. M., Shindo M., Fong T. L., Fried M. W., Swain M. G., Bergasa N. V., Axiotis C. A., Waggoner J. G., Park Y., Hoofnagle J. H. 1992; A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649–654
    [Google Scholar]
  7. Di Bisceglie A. M., Conjeevaram H. S., Fried M. W., Sallie R., Park Y., Yurdaydin C., Swain M., Kleiner D. E., Mahaney K., Hoofnagle J. H. 1995; Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 123:897–903
    [Google Scholar]
  8. Drach J. C., Barnett J. W., Thomas M. A., Smith S. H., Shipman C. 1980; Inhibition of viral and cellular DNA synthesis by ribavirin. In Ribavirin: A Broad Spectrum Antiviral Agent pp 119–128 Smith R. A., Kirkpatrick W. Edited by San Francisco: Academic Press;
    [Google Scholar]
  9. Dusheiko G., Main J., Thomas H., Reichard O., Lee C., Dhillon A., Rassam S., Fryden A., Reesink H., Bassendine M., Norkrans G., Cuypers T., Lelie N., Telfer P., Watson J., Weegink C., Sillikens P., Weiland O. 1996; Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. Journal of Hepatology 25:591–598
    [Google Scholar]
  10. Englund J. A., Piedra P. A., Jefferson L. S., Wilson S. Z., Taber L. H., Gilbert B. E. 1990; High -dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. Journal of Pediatrics 117:313–320
    [Google Scholar]
  11. Fairbanks L. D., Bofill M., Ruckemann K., Simmonds H. A. 1995; Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. Journal of Biological Chemistry 270:29682–29689
    [Google Scholar]
  12. Fried M. W., Fong T. L., Swain M. G., Park Y., Beames M. P., Banks S. M., Hoofnagle J. H., Di Bisceglie A. M. 1994; Therapy of chronic hepatitis B with a 6-month course of ribavirin. Journal of Hepatology 21:145–150
    [Google Scholar]
  13. Heagy W., Crumpacker C., Lopez P. A., Finberg R. W. 1991; Inhibition of immune functions by antiviral drugs. Journal of Clinical Investigation 87:1916–1924
    [Google Scholar]
  14. Hosoya M., Shigeta S., Ishii T., Suzuki H., De Clercq E. 1993; Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo. Journal of Infectious Diseases 168:641–646
    [Google Scholar]
  15. Hultgren C., Milich D. R., Sällberg M. 1997; Antibodies to hepatitis B e (HBeAg) can be induced in HBeAg transgenic mice by adoptive transfer of a specific T-helper 2 cell clone. Clinical and Diagnostic Laboratory Immunology 4:630–632
    [Google Scholar]
  16. Japour A. J., Lertora J. J., Meehan P. M., Erice A., Connor J. D., Griffith B. P., Clax P. A., Holden-Wiltse J., Hussey S., Walesky M., Cooney E., Pollard R., Timpone J., McLaren C., Johanneson N., Wood K., Booth D., Bassiakos Y., Crumpacker C. S. 1996; A phase-1 study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 13:235–246
    [Google Scholar]
  17. Jiang Z. L., Kunimoto M., Patel J. A. 1998; Autocrine regulation and experimental modulation of interleukin-6 expression by human pulmonary epithelial cells infected with respiratory syncytial virus. Journal of Virology 72:2496–2499
    [Google Scholar]
  18. Jin L., Peterson D. L. 1995; Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Archives of Biochemistry and Biophysics 323:47–53
    [Google Scholar]
  19. Jin L., Wei X., Gomez J., Datta M., Birkett A., Peterson D. L. 1995; Use of alpha-N,N-bis[carboxymethyl]lysine-modified peroxidase in immunoassays. Analytical Biochemistry 229:54–60
    [Google Scholar]
  20. Kakumu S., Yoshioka K., Wakita T., Ishikawa T., Takayanagi M., Higashi Y. 1993; Pilot study of ribavirin and interferon-beta for chronic hepatitis B. Hepatology 18:258–263
    [Google Scholar]
  21. Lai M. Y., Kao J. H., Yang P. M., Wang J. T., Chen P. J., Chan K. W., Chu J. S., Chen D. S. 1996; Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 111:1307–1312
    [Google Scholar]
  22. Mastronarde J. G., Monick M. M., Gross T. J., Hunninghake G. W. 1996; Amiloride inhibits cytokine production in epithelium infected with respiratory syncytial virus. American Journal of Physiology 271:L201–L207
    [Google Scholar]
  23. Milich D. R., McLachlan A., Thornton G. B., Hughes J. L. 1987; Immune response to hepatitis B virus core antigen HBcAg: localization of T cell recognition sites within HBcAg/HBeAg. Journal of Immunology 139:1223–1231
    [Google Scholar]
  24. Milich D. R., McLachlan A., Stahl S., Wingfield P., Thornton G. B., Hughes J. L., Jones J. E. 1988; Comparative immunogenicity of hepatitis B virus core and e antigens. Journal of Immunology 141:3617–3624
    [Google Scholar]
  25. Milich D. R., Jones J. E., Hughes J. L., Price J., Raney A. K., McLachlan A. 1990; Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?. Proceedings of the National Academy of Sciences, USA 87:6599–6603
    [Google Scholar]
  26. Milich D. R., McLachlan A., Raney A. K., Houghten R., Thornton G. B., Maruyama T., Hughes J. L., Jones J. E. 1991; Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides. Proceedings of the National Academy of Sciences, USA 88:4348–4352
    [Google Scholar]
  27. Milich D. R., Peterson D. L., Schödel F., Jones J., Hughes J. L. 1995a; Preferential recognition of the hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent. Journal of Virology 69:2776–2785
    [Google Scholar]
  28. Milich D. R., Schödel F., Peterson D. L., Jones J., Hughes J. L. 1995b; Characterization of self-reactive T cells that evade tolerance in hepatitis B e antigen transgenic mice. European Journal of Immunology 25:1663–1672
    [Google Scholar]
  29. Milich D. R., Wolf S. F., Hughes J. L., Jones J. J. 1995c; Interleukin 12 suppresses autoantibody production by reversing helper T-cell phenotype in hepatitis B e antigen transgenic mice. Proceedings of the National Academy of Sciences, USA 92:6847–6851
    [Google Scholar]
  30. Milich D. R., Schödel F., Hughes J. L., Jones J. E., Peterson D. L. 1997; The hepatitis B virus core and e antigens elicit different Th cell subsets : antigen structure can affect Th cell phenotype. Journal of Virology 71:2192–2201
    [Google Scholar]
  31. Reichard O., Andersson J., Schvarcz R., Weiland O. 1991; Ribavirin treatment for chronic hepatitis C. Lancet 337:1058–1061
    [Google Scholar]
  32. Reichard O., Norkrans G., Fryden A., Braconier J. H., Sonnerborg A., Weiland O. 1998; Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 351:83–87
    [Google Scholar]
  33. Ribavirin ARC Study Group 1993; Multicenter clinical trial of oral ribavirin in symptomatic HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 632–41
    [Google Scholar]
  34. Rodriguez W. J., Hall C. B., Welliver R., Simoes E. A., Ryan M. E., Stutman H., Johnson G., Van Dyke R., Groothuis J. R., Arrobio J. others 1994; Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebocontrolled trial. Journal of Pediatrics 125:129–135
    [Google Scholar]
  35. Sällberg M., Pushko P., Berzinsh I., Bichko V., Sillekens P., Noah M., Pumpens P., Grens E., Wahren B., Magnius L. O. 1993; Immunochemical structure of the carboxy-terminal part of hepatitis B e antigen: identification of internal and surface-exposed sequences. Journal of General Virology 74:1335–1340
    [Google Scholar]
  36. Sällberg M., Zhang Z.-X., Chen M., Jin L., Birkett A., Peterson D. L., Milich D. R. 1996; Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. Journal of General Virology 77:2721–2728
    [Google Scholar]
  37. Sällberg M., Townsend K., Chen M., O’Dea J., Banks T., Jolly D. J., Chang S. M., Lee W. T., Milich D. R. 1997; Characterization of humoral and CD4 + cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens. Journal of Virology 71:5295–5303
    [Google Scholar]
  38. Schödel F., Peterson D., Zheng J., Jones J. E., Hughes J. L., Milich D. R. 1993; Structure of hepatitis B virus core and e-antigen. A single precore amino acid prevents nucleocapsid assembly. Journal of Biological Chemistry 268:1332–1337
    [Google Scholar]
  39. Schvarcz R., Ando Y., Sonnerborg A., Weiland O. 1995; Combination treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. Journal of Hepatology 23:17–21
    [Google Scholar]
  40. Shigeta S., Mori S., Baba M., Ito M., Honzumi K., Nakamura K., Oshitani H., Numazaki Y., Matsuda A., Obara T. others 1992; Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosyl- imidazole-4-carboxamide, and 6ʹ-(R)-6ʹ-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrobial Agents and Chemotherapy 36:435–439
    [Google Scholar]
  41. Spanish Ribavirin Trial Group 1991; Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. Lancet 3386–9
    [Google Scholar]
  42. Srikiatkhachorn A., Braciale T. J. 1997; Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. Journal of Virology 71:678–685
    [Google Scholar]
  43. Stevens T. L., Bossie A., Sanders V. M., Fernandez-Botran R., Coffman R. L., Mossman T. R., Vitetta E. S. 1988; Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334:255–258
    [Google Scholar]
  44. Waris M. E., Tsou C., Erdman D. D., Zaki S. R., Anderson L. J. 1996; Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. Journal of Virology 70:2852–2860
    [Google Scholar]
  45. Zhang Z.-X., Chen M., Hultgren C., Birkett A., Milich D. R., Sällberg M. 1997a; Immune responses to the hepatitis C virus NS4A protein are profoundly influenced by the combination of the viral genotype and the host major histocompatibility complex. Journal of General Virology 78:2735–2746
    [Google Scholar]
  46. Zhang Z.-X., Milich D. R., Peterson D. L., Birkett A., Schvarcz R., Weiland O., Sällberg M. 1997b; Interferon-alpha treatment induces delayed CD4+ proliferative responses to the hepatitis C virus non-structural 3 protein regardless of the outcome of therapy. Journal of Infectious Diseases 175:1294–1301
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-79-10-2381
Loading
/content/journal/jgv/10.1099/0022-1317-79-10-2381
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error